A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions

Journal of the American Dental Association

Volumn 141, Issue 2, 2010, Pages 151-156

  Mehrotra, Ravi ^a   Singh, Mamta ^a   Thomas, Shaji ^b   Nair, Preeti ^b   Pandya, Shruti ^a   Nigam, Niraj Shakti ^c   Shukla, Pankaj ^d  

^a MLN MEDICAL COLLEGE   (India)

^b PEOPLE S COLLEGE OF DENTAL SCIENCES AND RESEARCH CENTRE   (India)

^c District Hospital ^*

^d District Hospital   (India)

Author keywords

Dysplasia; Oral cancer; Oral cancer screening aids

Indexed keywords

EID: 77949285607     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2010.0132     Document Type: Article

References (24)

1. Robinson PN, Mickelson AR. Early diagnosis of oral cavity cancers. Otolaryngol Clin North Am 2006;39(2):295-306.
2. American Cancer Society. Estimated new cancer cases and deaths by sex, US, 2008. Available at: " www.cancer.org/downloads/stt/CFF2008Table-pg4. pdf". Accessed Dec. 17, 2009.
3. Mehrotra R, Pandya S, Chaudhary AK, Kumar M, Singh M. Prevalence of oral pre-malignant and malignant lesions at a tertiary level hospital in Allahabad, India. Asian Pac J Cancer Prev 2008;9(2):263-265.
4. 4. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008;44(1):10-22. (Pubitemid 350258631)
5. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. JADA 2008;139(7):896-905.
6. U.S. Department of Health and Human Services. 510(k) clearances. Rockville, Md.: U.S. Department of Health and Human Services, U.S. Food and Drug Administration, "www.fda.gov/cdrh/510khome.html". Accessed Dec. 17, 2009.
7. U.S. Department of Health and Human Services. Indications for use. ViziLite Blue Oral Exam Product. Rockville, Md.: U.S. Department of Health and Human Services, Food and Drug Administration; 2005. "www.accessdata.fda. gov/cdrh-docs/pdf3/K033033.pdf". Accessed Jan. 3, 2010.
8. U.S. Department of Health and Human Services. Section 5-510(k) summary: K060920. Rockville, Md.: U.S. Department of Health and Human Services, Food and Drug Administration; 2006. Available at: "www.accessdata.fda.gov/cdrh-docs/ pdf6/K060920.pdf". Accessed Nov. 29, 2009.
9. Sciubba JJ. Improving detection of precancerous and cancerous oral lesions: computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. JADA 1999;130(10):1445-1457.
10. 10. Epstein JB, Gorsky M, Lonky S, Silverman S Jr, Epstein JD, Bride M. The efficacy of oral lumenoseopy (ViziLite) in visualizing oral mucosal lesions. Spec Care Dentist 2006;26(4):171-174. (Pubitemid 44476718)
11. Oh ES, Laskin DM. Efficacy of the ViziLite system in the identification of oral lesions. J Oral Maxillofac Surg 2007;65(3):424-426.
12. Farah CS, McCullough MJ. A pilot case control study on the efficacy of acetic acid wash and chemiluminescent illumination (ViziLite) in the visualisation of oral mucosal white lesions. Oral Oncol 2007;43(8): 820-824.
13. Kerr AR, Sirois DA, Epstein JB. Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. J Clin Dent 2006;17(3):59-63.
14. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol 2008;44(6): 538-544.
15. Zila, a Division of Tolmar. ViziLite Plus with TBlue package insert. Intended use. " www.zila.com/UserFiles/File/ViziliteBlueTBlue630.pdf". Accessed Jan. 3, 2010.
16. Andersson-Engels S, Klinteberg C, Svanberg K, Svanberg S. In vivo fluorescence imaging for tissue diagnostics. Phys Med Biol 1997; 42(5):815-824.
17. 17. Pavlova I, Williams M, El-Naggar A, Richards-Kortum R, Gillenwater A. Understanding the biological basis of autofluorescence imaging for oral cancer detection: high-resolution fluorescence microscopy in viable tissue. Clin Cancer Res 2008;14(8):2396-2404. (Pubitemid 351551073)
18. Chen CT, Chiang HK, Chow SN, et al. Autofluorescence in normal and malignant human oral tissues and in DMBA-induced hamster buccal pouch carcinogenesis. J Oral Pathol Med 1998;27(10):470-474.
19. 19. Franzen S, Boxer SG. On the origin of heme absorption band shifts and associated protein structural relaxation in myoglobin following flash photolysis. J Biol Chem 1997;272(15):9655-9660. (Pubitemid 27171625)
20. Huat SC, Ping-Ann OV, Hitoshi N, et al. Angiogenic squamous dysplasia in oral epithelial dysplastic lesions. J Hard Tissue Biol 2005; 14(2):185-186.
21. Huff K, Stark PC, Solomon LW. Sensitivity of direct tissue fluorescence visualization in screening for oral premalignant lesions in general practice. Gen Dent 2009;57(1):34-38.
22. 22. Lane PM, Gilhuly T, Whitehead P, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt 2006;11(2):024006. (Pubitemid 44355086)
23. Balevi B. Evidence-based decision making: should the general dentist adopt the use of the VELscope for routine screening for oral cancer? J Can Dent Assoc 2007;73(7):603-606.
24. LED Dental. Index of/pdf/ guides. "www.velscope.com/pdf/guides/ ". Accessed Jan. 3, 2010.